Estamos realizando la búsqueda. Por favor, espere...
1583
37
170
29013
4402
2599
347
386
Abstract: B-cell maturation antigen (BCMA) is an ideal target in multiple myeloma (MM) due to highly specific expression in malignant plasma cells. BCMA-directed therapies including antibody drug conjugates, chimeric antigen receptor-T cells and bispecific antibodies (BsAbs) have shown high response rates in MM. WVT078 is an anti-BCMA× anti-CD3 BsAb that binds to BCMA with subnanomolar-affinity. It was selected based on potent T cell activation and anti-MM activity in preclinical models with favorable tolerability in cynomolgus monkey. In the ongoing first-in-human phase I dose-escalation study (NCT04123418), 33 patients received intravenous WVT078 once weekly at escalated dosing. At the active doses of 48-250 µg/kg tested to date (n = 26), the overall response rate (ORR) was 38.5% (90% CI: 22.6-56.4%) and the complete response rate (CRR, stringent complete response + complete response) was 11.5%, (90% CI: 3.2-27.2%). At the highest dose level tested, the ORR was 75% (3 of 4 patients). 26 (78.8%) patients reported at least one Grade ?3 AE and 16 of these AEs were suspected to be drug related. 20 patients (60.6%) experienced cytokine release syndrome. WVT078 has an acceptable safety profile and shows preliminary evidence of clinical activity at doses tested to date.
Fuente: Leukemia, 2023, 37, 1349-1360
Editorial: Nature Publishing Group
Año de publicación: 2023
Nº de páginas: 12
Tipo de publicación: Artículo de Revista
DOI: 10.1038/s41375-023-01883-3
ISSN: 0887-6924,1476-5551
Url de la publicación: https://doi.org/10.1038/s41375-023-01883-3
Leer publicación
RAAB, MARC S.
COHEN, YAEL C.
SCHJESVOLD, FREDRIK
AARDALEN, KIMBERLY
OKA, ADWAIT
SPENCER, ANDREW
WERMKE, MARTIN
SOUZA, ANITA D.
KAUFMAN, JONATHAN L.
CAFRO, ANNA MARIA
ENRIQUE MARIA OCIO SAN MIGUEL
DOKI, NORIKO
HENSON, KRISTIN
TRABUCCO, GINA
CARRION, ANA
BENDER, FLORENT C.
JUIF, PIERRE-ERIC
FESSEHATSION, ADONAI
FAN, LIQUIONG
STONEHOUSE, JEFFREY P.
Volver